Global Invasive Fungal Infection Market Opportunities and Forecast 2020-2027

  • DLR2870
  • 06 December, 2021
  • Pharma & Healthcare
  • Pages: 120
  • Global
Global Invasive Fungal Infection Market, By Disease Type (Candidemia, Invasive Candidiasis, Intra-abdominal candidiasis (CandidaPeritonitis), Cryptococcal Meningitis, Histoplasmosis Disseminated, Histoplasmosis Acute Pulmonary, Invasive aspergillosis, Invasive Rhinosinusitis, Mucormycosis, Pneumocystis Pneumonia, Others.), By Application (Hospital, Clinics, Others), and opportunities and forecast 2020-2027

Invasive Fungal Infection Market Overview

The rise in population full of HIV/AIDS, discovery and advancement of pipeline drugs and facilities provided by hospitals in medical care units for people who have undergone surgery, surge in chemotherapy and increase in use of broad spectrum antibiotics and economic growth economic process goes to accelerate the invasive mycosis market. Introduction of advanced medicines has already well-tried to be constructive proven directly improves the health of immuno-compromised patient and enhances the global of a patient.

The Invasive fungal infection market has been calculable to witness growth in future primarily thanks to surging demand for affordable pipeline merchandise and increase in use of broad-spectrum antibiotics that makes fungi resistant to varied medicines and to choose the affordable medicines whose effect will last longer than the traditional medicines.

Report Metric Details
Market size available for years 2019–2027
Base year considered 2019
Forecast period 2020–2027
Forecast unit Value (USD Million)
Segments covered Disease Type, Application, and Region
Regions covered North America (the U.S. and Canada), Europe (UK, Germany, France, Italy, Spain, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, Australia, South East Asia, Rest of Asia Pacific), Latin America and the Middle East and Africa (Brazil, Saudi Arabia, UAE, Rest of LAMEA)
Companies covered Cidara, Basilea Pharmaceutica, Pfizer, GlaxoSmith Kline, Bayer AG, Abott, Merck & Co., Astellas Pharma Inc., F2G - The Rare Fungal Disease Company, Scynexis Inc.


The covid-19 Impact on Invasive Fungal Infection Market:

Whereas, the chemicals and accouterments sectors were relatively affected during the pandemic. This is primarily due to uncut demand for chemicals for healthcare, life wisdom, and drawing agents. However, other elements of chemical and material sectors such as types of paints, industrial oil, construction materials are facing reduction in demand. Strict lockdown reflected in a nearly 50-60% reduction in force for raw supply and availability, which directly affected the manufacturing process. Further, halt on numerous end-use diligence directly affected the chemical demand each around the world.
 
Invasive Fungal Infection Market Segment Overview



By Disease Type,Candidemia segment accounted major market share owing to fungal diseases and increasing awareness .
 
By  Application,Hospital segment accounted major market share owing to increasing healthcare infrastructure and  discovery and advancement of pipeline drugs and facilities.
 
Market Analysis, Insights and Forecast – By Disease Type
·       Candidemia
·       Invasive Candidiasis,
·       Intra-abdominal candidiasis (Candida Peritonitis),
·       Cryptococcal Meningitis,
·       Histoplasmosis Disseminated,
·       Histoplasmosis Acute Pulmonary,
·       Invasive aspergillosis,
·       Invasive Rhinosinusitis,
·       Mucormycosis,
·       Pneumocystis Pneumonia,
·       Others.

Market Analysis, Insights and Forecast – By Application
·       Hospital
·       Clinics
·       Others

Invasive Fungal Infection Market Regional Overview

Region-wise, in terms of regions ,Across the region ,market expanded all regions in North  America market segmented into the US and Canada .Additionally,Europe region market segmented into the UK ,Germany,France,Italy,Spain, and Rest of Europe,Asia - Pacific region segmented into japan,china,india,australia,south korea and rest of asia - pacific and LAMEA segmented into brazil,saudi arabia, UAE and rest of LAMEA.

Invasive Fungal Infection Market, By Geography

·       North America (US & Canada)
·       Europe (UK, Germany, France, Italy, Spain, & Rest of Europe)
·       Asia-Pacific (Japan, China, India, Australia, & South Korea, & Rest of Asia-Pacific)
·       LAMEA (Brazil, Saudi Arabia, UAE & Rest of LAMEA)
 
Invasive Fungal Infection Market Competitor overview

Some key developments and strategies adopted by manufacturers in the Invasive Fungal Infection market highlighted below.

·       In 2021,  Pfizer Inc.  acquired Amplyx Pharmaceuticals, Inc., this is resulting to the development of therapies for debilitating and life-threatening diseases that affect people with compromised immune systems.

Invasive Fungal Infection Market, Key Players -

·       Cidara
·       Basilea Pharmaceutica
·       Pfizer
·       GlaxoSmith Kline
·       Bayer AG
·       Abott
·       Merck & Co.
·       Astellas Pharma Inc.
·       F2G - The Rare Fungal Disease Company
·       Scynexis Inc.
 
 

Frequently Asked Questions (FAQ) :

Q1. What is the total CAGR expected to be recorded for the Invasive Fungal Infection market during the forecast period?

A. Invasive Fungal Infection market is expected to record a CAGR of ~ xx % during the forecast period.

Q2. Which segment is projected to hold the largest share in the Invasive Fungal Infection Market?

A. Hospital segment is projected to hold the largest share in the Invasive Fungal Infection Market.

Q3. What are the driving factors for the Invasive Fungal Infection market?

A. The increasing healthcare infrastructure and discovery and advancement of pipeline drugs and facilities these are main factors driving the growth of automotive lighting market

Q4. Which Segments are covered in the Invasive Fungal Infection market report?

A. Disease Type , Application and Region, these segments are covered in the Invasive Fungal Infection market report

Q5. Which are the prominent players offering the Invasive Fungal Infection market?

A. Cidara,Basilea Pharmaceutica,Pfizer,GlaxoSmith Kline ,Bayer AG,Abott,Merck & Co., Astellas Pharma Inc.,F2G - The Rare Fungal Disease Company,Scynexis Inc
Invasive Fungal Infection Market Study Global Market Analysis, Insights and Forecast, 2020-2027

    1. Introduction

    • 1.1. Research Scope
    • 1.2. Market Segmentation
    • 1.3. Research Methodology
    • 1.4. Definitions and Assumptions

    2. Executive Summary

      3. Market Dynamics

      • 3.1. Market Drivers
      • 3.2. Market Restraints
      • 3.3. Market Opportunities

      4. Key Insights

      • 4.1. Key Emerging Trends – For Major Countries
      • 4.2. Latest Technological Advancement
      • 4.3. Regulatory Landscape
      • 4.4. Industry SWOT Analysis
      • 4.5. Porters Five Forces Analysis

      5. Global Invasive Fungal Infection Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 5.1. Key Findings / Summary
      • 5.2. Market Analysis, Insights and Forecast – By Disease Type
        • 5.2.1. Candidemia
        • 5.2.2. Invasive Candidiasis,
        • 5.2.3. Intra-abdominal candidiasis (Candida Peritonitis),
        • 5.2.4. Cryptococcal Meningitis,
        • 5.2.5. Histoplasmosis Disseminated,
        • 5.2.6. Histoplasmosis Acute Pulmonary,
        • 5.2.7. Invasive aspergillosis,
        • 5.2.8. Invasive Rhinosinusitis,
        • 5.2.9. Mucormycosis
        • 5.2.10. Pneumocystis Pneumonia
        • 5.2.11. Others.
      • 5.3. Market Analysis, Insights and Forecast – By Application
        • 5.3.1. Hospital
        • 5.3.2. Clinics
        • 5.3.3. Others
      • 5.4. Market Analysis, Insights and Forecast – By Region
        • 5.4.1. North America
        • 5.4.2. Europe
        • 5.4.3. Asia Pacific
        • 5.4.4. Latin America, Middle East, and Africa

      6. North America Invasive Fungal Infection Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 6.1. Key Findings / Summary
      • 6.2. Market Analysis, Insights and Forecast – By Disease Type
        • 6.2.1. Candidemia
        • 6.2.2. Invasive Candidiasis,
        • 6.2.3. Intra-abdominal candidiasis (Candida Peritonitis),
        • 6.2.4. Cryptococcal Meningitis,
        • 6.2.5. Histoplasmosis Disseminated,
        • 6.2.6. Histoplasmosis Acute Pulmonary,
        • 6.2.7. Invasive aspergillosis,
        • 6.2.8. Invasive Rhinosinusitis,
        • 6.2.9. Mucormycosis
        • 6.2.10. Pneumocystis Pneumonia
        • 6.2.11. Others.
      • 6.3. Market Analysis, Insights and Forecast – By Application
        • 6.3.1. Hospital
        • 6.3.2. Clinics
        • 6.3.3. Others
      • 6.4. Market Analysis, Insights and Forecast – By Country
        • 6.4.1. UK
        • 6.4.2. Germany
        • 6.4.3. France
        • 6.4.4. Italy
        • 6.4.5. Spain
        • 6.4.6. Russia
        • 6.4.7. Rest of Europe

      7. Asia Pacific Invasive Fungal Infection Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 7.1. Key Findings / Summary
      • 7.2. Market Analysis, Insights and Forecast – By Disease Type
        • 7.2.1. Candidemia
        • 7.2.2. Invasive Candidiasis,
        • 7.2.3. Intra-abdominal candidiasis (Candida Peritonitis),
        • 7.2.4. Cryptococcal Meningitis,
        • 7.2.5. Histoplasmosis Disseminated,
        • 7.2.6. Histoplasmosis Acute Pulmonary,
        • 7.2.7. Invasive aspergillosis,
        • 7.2.8. Invasive Rhinosinusitis,
        • 7.2.9. Mucormycosis
        • 7.2.10. Pneumocystis Pneumonia
        • 7.2.11. Others.
      • 7.3. Market Analysis, Insights and Forecast – By Application
        • 7.3.1. Hospital
        • 7.3.2. Clinics
        • 7.3.3. Others
      • 7.4. Market Analysis, Insights and Forecast – By Country
        • 7.4.1. China
        • 7.4.2. India
        • 7.4.3. Japan
        • 7.4.4. Australia
        • 7.4.5. South East Asia
        • 7.4.6. Rest of Asia Pacific

      8. Latin America, Middle East, and Africa Invasive Fungal Infection Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 8.1. Key Findings / Summary
      • 8.2. Market Analysis, Insights and Forecast – By Disease Type
        • 8.2.1. Candidemia
        • 8.2.2. Invasive Candidiasis,
        • 8.2.3. Intra-abdominal candidiasis (Candida Peritonitis),
        • 8.2.4. Cryptococcal Meningitis,
        • 8.2.5. Histoplasmosis Disseminated,
        • 8.2.6. Histoplasmosis Acute Pulmonary,
        • 8.2.7. Invasive aspergillosis,
        • 8.2.8. Invasive Rhinosinusitis,
        • 8.2.9. Mucormycosis
        • 8.2.10. Pneumocystis Pneumonia
        • 8.2.11. Others.
      • 8.3. Market Analysis, Insights and Forecast – By Application
        • 8.3.1. Hospital
        • 8.3.2. Clinics
        • 8.3.3. Others
      • 8.4. Market Analysis, Insights and Forecast – By Country
        • 8.4.1. Brazil
        • 8.4.2. Saudi Arabia
        • 8.4.3. UAE
        • 8.4.4. Rest of LAMEA

      9. Competitive Analysis

      • 9.1. Company Market Share Analysis, 2018
      • 9.2. Key Industry Developments
      • 9.3. Company Profile
      • 9.4. Cidara
        • 9.4.1. Business Overview
        • 9.4.2. Segment 1 & Service Offering
        • 9.4.3. Overall Revenue
        • 9.4.4. Geographic Presence
        • 9.4.5. Recent Development
      *Similar details will be provided for the following companies
      • 9.5. Basilea Pharmaceutica
      • 9.6. Pfizer
      • 9.7. GlaxoSmith Kline
      • 9.8. Bayer AG
      • 9.9. Abott
      • 9.10. Merck & Co.
      • 9.11. Astellas Pharma Inc.
      • 9.12. F2G - The Rare Fungal Disease Company

      Report You Might be Interested

      Choose License Type

      • USD
      • GBP
      • EURO
      • INR
      Credit card Logo

      Happy To Assist You

      Have a Question? email us at

      info@datalibraryresearch.com

      Or Call Us On

      US +1 360 851 1343

      IND +91 880 579 4934